Overview

The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19

Status:
Recruiting

Trial end date:
2024-04-01

Target enrollment:

Participant gender:

Summary

This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of Nintedanib on slowing the rate of lung disease in patients who have been diagnosed with COVID-19, and have ongoing lung injury more than 4 weeks out from their diagnosis.

Phase:

Phase 4

Details

Lead Sponsor:

Icahn School of Medicine at Mount Sinai

Collaborator:

Boehringer Ingelheim

Treatments:

Nintedanib